Results 1 to 10 of about 8,830 (256)

Association of Cholinergic Muscarinic M4 Receptor Gene Polymorphism with Schizophrenia [PDF]

The Application of Clinical Genetics, 2020
Ivan V Pozhidaev,1,2 Anastasiia S Boiko,1 Anton JM Loonen,3 Diana Z Paderina,1,2 Olga Yu Fedorenko,1,4 Gennadiy Tenin,5 Elena G Kornetova,1,6 Arkadiy V Semke,1 Nikolay A Bokhan,1,2,6 Bob Wilffert,3,7 Svetlana A Ivanova1,4,6 1Mental Health Research ...
Pozhidaev IV, Boiko AS, Loonen AJM, Paderina DZ, Fedorenko OY, Tenin G, Kornetova EG, Semke AV, Bokhan NA, Wilffert B, Ivanova SA   +10 more
doaj   +5 more sources

Postsynaptic adaptations in direct pathway muscarinic M4-receptor signaling follow the temporal and regional pattern of dopaminergic degeneration [PDF]

npj Parkinson's Disease
In Parkinson’s disease (PD), imbalances in dorsal striatum pathways are thought to lead to motor dysfunction due to loss of dopamine (DA) and the disruption of coordinated modulation with acetylcholine (ACh).
Beatriz E. Nielsen, Christopher P. Ford
doaj   +3 more sources

Striatal M4 muscarinic receptors determine the biological rhythm of activity, with a supportive role of M1 muscarinic receptors [PDF]

Frontiers in Pharmacology
IntroductionM4 muscarinic receptor (mAChR) knockout changed the female activity biological rhythm parameters. In this study, we focus on the biological rhythms of mAChRs (total + M1 mAChRs), acetylcholinesterase (AChE), and butyrylcholinesterase (BuChE ...
Katerina Janisova, Monika Uhlirova, Sandor Forczek, Jaromir Myslivecek   +3 more
doaj   +4 more sources

Pharmacological hallmarks of allostery at the M4 muscarinic receptor elucidated through structure and dynamics

eLife, 2023
Allosteric modulation of G protein-coupled receptors (GPCRs) is a major paradigm in drug discovery. Despite decades of research, a molecular-level understanding of the general principles that govern the myriad pharmacological effects exerted by GPCR ...
Ziva Vuckovic, Jinan Wang, Vi Pham, Jesse I Mobbs, Matthew J Belousoff, Apurba Bhattarai, Wessel AC Burger, Geoff Thompson, Mahmuda Yeasmin, Vindhya Nawaratne, Katie Leach, Emma T van der Westhuizen, Elham Khajehali, Yi-Lynn Liang, Alisa Glukhova, Denise Wootten, Craig W Lindsley, Andrew Tobin, Patrick Sexton, Radostin Danev, Celine Valant, Yinglong Miao, Arthur Christopoulos, David M Thal   +23 more
doaj   +2 more sources

IUPHAR Review on muscarinic M1 and M4 receptors as drug treatment targets relevant to the molecular pathology of schizophrenia

Pharmacological Research
Cobenfy, a co-formulation of xanomeline and trospium, is the first drug not acting on the dopaminergic system of the CNS approved for the treatment of schizophrenia by the FDA.
Brian Dean
doaj   +2 more sources

Autoradiography of 3H-pirenzepine and 3H-AFDX-384 in Mouse Brain Regions: Possible Insights into M1, M2, and M4 Muscarinic Receptors Distribution [PDF]

Frontiers in Pharmacology, 2018
Autoradiography helps to determine the distribution and density of muscarinic receptor (MR) binding sites in the brain. However, it relies on the selectivity of radioligands toward their target.
Paulina Valuskova, Vladimir Farar, Sandor Forczek, Iva Krizova, Jaromir Myslivecek   +4 more
doaj   +2 more sources

Downstream Signaling of Muscarinic M4 Receptors Is Regulated by Receptor Density and Cellular Environment [PDF]

Pharmacology Research & Perspectives
Multiple muscarinic M4 receptor modulators are currently advancing in clinical development for the treatment of positive symptoms in schizophrenia, including agonists and positive allosteric modulators.
Madeleine Merz, Charlotte Playle, Monika Palchaudhuri, Oliver Hucke, Ulrike Gross, Daniel Ursu   +5 more
doaj   +2 more sources

A New Era of Muscarinic Acetylcholine Receptor Modulators in Neurological Diseases, Cancer and Drug Abuse [PDF]

Pharmaceuticals
The cholinergic pathways in the central nervous system (CNS) play a pivotal role in different cognitive functions of the brain, such as memory and learning.
Helena Tsimpili, Grigoris Zoidis
doaj   +2 more sources

Xanomeline/trospium-induced polyuria: A patient case report [PDF]

Mental Health Clinician
Xanomeline/trospium is a newly approved agent for the management of schizophrenia. Unlike traditional antipsychotics, which are D2 receptor antagonists, xanomeline is an M1/M4 muscarinic acetylcholine receptor agonist coformulated with trospium, a ...
Henry Leach, PharmD, BCPP, Francesca DiGuglielmo, PharmD   +1 more
doaj   +2 more sources

Synergistic mechanisms of medullary cholinergic-serotonergic pathway interactions in regulating neuronal excitability and locomotor activities [PDF]

Communications Biology
Medullary serotonergic (5-HT) neurons play a pivotal role in locomotor initiation. While these neurons receive cholinergic innervation, the functional consequences and underlying mechanisms remain poorly understood. Using ePet-EYFP transgenic mice (P3–P6)
Yi Cheng, Yue Dai, Renkai Ge, Qiang Zhang   +3 more
doaj   +2 more sources